How much funding has Agios raised?

Agios has raised $78.0M in total funding, most recently a Series C round.

Who are Agios's investors?

Agios's investors include Flagship Pioneering, Third Rock Ventures.

Where is Agios headquartered?

Agios is headquartered in Cambridge, Massachusetts, United States.

What industry is Agios in?

Agios operates in Biotech, Healthcare.

Agios

Fueled by Connections to Transform Rare Diseases™

Cambridge, United States · Founded 2008 · $78.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Founded: 2008
Business Model: B2B

Total Funding: $78.0M
Last Round: $78.0M Series CNov 2011
Rounds: 1

About

Agios is a commercial-stage biopharmaceutical company pioneering therapies for patients with rare diseases, with a near-term focus on hemolytic and acquired anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease. Founded in 2008 and headquartered in Cambridge, Massachusetts, Agios has been a leading innovator in the field of cellular metabolism since its inception, translating deep scientific understanding into life-changing medicines. The company builds close relationships with patient communities, healthcare professionals, and partners to ensure therapies address unmet needs and deliver maximum impact.

Summary

Agios is a Biotech company based in Cambridge, United States, founded in 2008. It has raised $78.0M in total across 1 round, most recently a $78.0M Series C round in Nov 2011. Investors include Flagship Pioneering and Third Rock Ventures.